Monte Rosa Therapeutics
Developing next-generation small molecule protein degraders to treat cancer and beyond.
HQ location
Boston, United States
Website
Launch date
Employees
Market cap
$282m
Enterprise value
($2m)
Share price
$4.51 GLUE
Company register number
CHE-405.675.696
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $100m | Post IPO Equity |
| Total Funding | 000k | ||
Versant Ventures(exited)
NEA(exited)
Aisling Capital(exited)
Cormorant Asset Management(exited)
GV(exited)
Amzak Health Investors(exited)
Casdin Capital(exited)
Sixty Degree Capital(exited)
CI Global Asset Management(exited)
Avoro Capital Advisors(exited)
Fidelity Investments(exited)
BlackRock(exited)
T. Rowe Price(exited)
RTW Investments(exited)
Cambridge Asset Management(exited)
HBM Partners(exited)
Amzak Health(exited)
Ridgeline Discovery(exited)
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | 57 % | (62 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | (97 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | (96 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | - | - | 161 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.